NCT06554301

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: China National Center for Cardiovascular Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin. The main questions it aims to answer are: Based on standard treatment, does empagliflozin reduce pulmonary artery pressure and improve cardiac function in patients with pulmonary arterial hypertension? What medical problems do participants have when taking empagliflozin? Researchers will compare empagliflozin to a placebo (a look-alike substance that contains no drug) to see if empagliflozin works to treat patients with pulmonary arterial hypertension. Participants will: Take empagliflozin or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the drug taking situation

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	empagliflozin in treatment pulmonary aerterial hypertension	On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
DRUG	placebo in treatment pulmonary aerterial hypertension	On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.

Timeline

• Start date: 2024-10-20
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-08-15
• Last updated: 2026-03-19

Locations

1 site across 1 country: China